查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840598

抗病毒治疗市场依疾病类型、药物类别、给药途径、通路和治疗类型划分－2025-2032年全球预测

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗病毒治疗市场规模将达到 1,570.2 亿美元，复合年增长率为 8.45%。

主要市场统计数据
基准年 2024 820.1亿美元
预计年份：2025年 888.9亿美元
预测年份：2032年 1570.2亿美元
复合年增长率 (%) 8.45%

为决策者提供最新的抗病毒治疗领域全面说明，整合科学进展、监管现状和商业策略。

抗病毒治疗领域正处于科学发现加速发展、公共卫生期望不断变化以及竞争日益激烈的交汇点。近期趋势表明，新型疗法和给药技术正从概念验证迈向临床阶段，这为研发者、生产者和支付者创造了一个更复杂但也充满机会的环境。如今，相关人员必须权衡治疗方法创新与成本压力、供应链脆弱性以及全球主要司法管辖区不断变化的监管标准之间的关係。

随着病原体频谱的扩大和应对疫情的重要性日益凸显，企业必须重新调整策略重点。对频谱平台、宿主标靶疗法和适应性生产的投资正日益增加。同时，支付者和采购机构也越来越重视临床价值和真实世界疗效，促使申办者设计超越关键性临床试验的证据产生策略。因此，兼具科学严谨性、商业性远见和营运韧性的领导者将引领抗病毒疗法研发和应用的下一阶段。

平台技术、监管改革和生产灵活性的整合如何从根本上改变抗病毒药物的发现、开发和递送

一系列变革性变化正在重塑抗病毒药物的发现、开发和递送方式。在疫情期间展现出良好适应性的平台技术，如今正被重新应用于更广泛的病毒，从而加快先导化合物的筛选速度，并优化药物开发流程。同时，日趋成熟的单株抗体工程技术和宿主定向疗法的改进，也为传统小分子抑制剂以外的治疗选择提供了更多可能。

数位化能力和人工智慧正在加速标靶发现并优化候选药物筛选，而模组化和一次性生产解决方案则缩短了前置作业时间并提高了地域灵活性。这些科学和营运方面的变革与监管创新相辅相成，快速审批途径和适应性测试设计促进了对未满足医疗需求高的适应症的有条件准入。总而言之，这些变革共同描绘出一幅技术融合、监管灵活性和生产适应性将决定商业性成败的格局。

评估近期美国关税措施对抗病毒药物供应链、采购和生产决策的累积营运和策略影响

2025年实施的政策变革和贸易措施为全球抗病毒药物供应链和筹资策略引入了新的变数。影响关键原料和成品药的关税调整增加了跨境采购的成本，促使企业重新评估其供应商网路和库存策略。为此，许多企业正在加快降低单一来源风险的步伐，包括本地化生产、扩大与製造外包的合作以及实现原料药供应商多元化。

关税不仅影响直接成本，也影响长期的策略选择。赞助商和製造商正在重新评估新设施的位置，将关税风险与劳动力、人才供应和监管合规性等因素纳入考量。医院、零售药局和专科诊所的采购机构正在调整合约方式，在供应保证和价格上涨机制方面提供更大的灵活性。贸易措施的累积影响凸显了建立具有韧性的多层次供应策略的必要性，这些策略既能确保医疗服务的连续性，又能维持商业性可行性。

将疾病标靶、药物类别、给药途径、分销管道和治疗目的与临床和商业性决策联繫起来的策略性细分洞察

主导细分市场的分析揭示了不同治疗标靶和治疗方式的差异化动态，从而为产品组合和商业化选择提供基础。急性呼吸道病毒感染需要快速起效和便捷给药，而慢性感染疾病（如C型肝炎和爱滋病）则更注重持续性病毒抑制、依从性支持和抗药性管理。巨细胞病毒和呼吸道融合细胞病毒等新发和再发病毒需要专门的临床开发方法，并且通常受益于标靶生技药品和预防策略。

不同药物类别的差异会影响研发週期和上市推广。小分子聚合酵素和蛋白酶抑制剂具有口服给药和成熟生产流程的优势，而单株抗体和干扰素通常需要注射剂型和复杂的生技药品生产过程。融合酶和整合酶抑制剂，以及核苷类和非核苷类逆转录酶抑制剂，各自具有不同的抗药性谱和联合治疗方案。口服製剂便于透过门诊和零售药局进行分销，而注射剂通常需要医院或专科诊所的参与，吸入和局部用药则适用于特定的呼吸系统和局部适应症。给药途径直接影响健保报销管道和病人偏好。

分销通路策略必须与产品特性和医疗保健系统能力相符。医院药局和专科诊所在肠外生技药品和需要监测的复杂疗法方面发挥关键作用，而零售药局和线上药局则扩大了口服抗病毒药物和预防性药物的可及性。最后，治疗目的（预防或治疗）会影响临床试验设计、标籤细微差别和上市后证据的产生。预防性药物通常着重于人群层面的疗效和长期安全性，而治疗性药物则优先考虑即时临床终点和抗药性监测。整合这些细分市场有助于实现有针对性的临床开发、量身定制的上市计划和最佳的商业部署。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和市场准入需求影响着开发、製造和商业化选择。

区域差异造就了截然不同的营运和法规环境，进而影响研发管线的优先排序和市场进入策略。美洲拥有完善的临床试验基础设施、大量的公共和私人研发投资，以及复杂的报销体系，这些都要求以实证医学为基础，证明其疗效和价值优于现有标准疗法。该地区的监管管道也为优先疗法提供了早期准入机制，但相关人员必须应对价格审查和支付方主导的使用控制。

欧洲、中东和非洲的法律规范和采购模式各不相同，有些市场专注于集中评估，而有些市场则依赖国家评估和竞标流程。这种多样性要求制定细緻入微的打入市场策略，以平衡区域申请文件、国家层级的证据和定价弹性。在亚太地区，创新平台的快速普及、生物製造基础的不断壮大以及公私医疗保健投资的持续增长，为战略伙伴关係和区域製造中心的建设创造了沃土。监管时间表、智慧财产权保护和当地临床实践模式的差异，使得制定个人化的商业化蓝图势在必行。在所有地区，跨境贸易措施、当地生产奖励以及数位医疗的普及应用将继续影响供应链设计和市场准入顺序。

公司层面的当务之急，展现了大型製药网络、专业生物技术和製造合作伙伴如何携手合作，推动抗病毒药物的创新和商业化。

企业策略揭示了一个分叉的生态系统：大型综合製药公司和灵活的生物技术公司各自追求互补的创新路径。大型跨国公司利用其深厚的监管专业知识、广泛的生产网络和全球商业性影响力，推动后期专案并扩大复杂生技药品的生产规模。同时，专注于具有影响力的科学研究、罕见或孤儿病毒靶点以及颠覆性治疗方法的生物技术公司，越来越依赖战略联盟、许可协议和里程碑式的合作来加速临床开发并获取资金。

受託製造厂商)已成为至关重要的生态系统合作伙伴，它们能够帮助企业快速扩大规模并实现地域多元化，而无需承担新建设施的固定成本。此外，专注于递送技术、诊断和数据主导临床优化的新兴参与企业正在重塑企业建立其价值提案的方式。在这种竞争激烈的环境中，成功的企业正在将科学差异化与切实可行的商业化计划相结合，优先考虑建立持久的生产合作关係，并产生核准后证据以支持其产品在不同医疗保健系统中的应用。

为高阶主管提供切实可行的跨职能建议，以增强抗病毒治疗价值链的韧性、加速药物取得并优化商业化。

产业领导者应采取整合策略，将科学差异化、营运韧性和以市场为导向的证据产生结合。首先，他们应实现关键原材料和生技药品成分供应商网路的多元化，同时建立双源协议和安全库存政策，以降低供应中断的风险。同时，他们应投资于灵活且地理分散的生产能力，包括与能够处理多种治疗方式的契约製造製造商合作。

第二，优先发展能够解决抗药性问题并拓宽治疗前景的平台技术和联合治疗，同时设计以真实世界终点和适应性要素为核心的临床项目，以支持加速药物取得。第三，透过优化管道以提高依从性、可近性和监控效果，使分销策略与产品特性相符。例如，将线上药局计画和数位依从性工具应用于口服药物，而注射用生技药品则透过提供综合患者支援的专科诊所进行分销。第四，制定能够体现产品全生命週期价值的定价和合约框架，尽可能纳入基于结果的要素，并预估区域支付方的要求。最后，加强跨职能协作，连结研发、监管、生产和商业团队，确保研发决策反映下游实际情况，并以实证策略支援产品的持续应用。

一项严谨的多方法研究途径，结合了主要相关人员研究、临床和监管审查、供应链分析以及迭代式同行检验，确保了研究结果的可操作性。

调查方法采用多种研究方法，结合一手资料和二手资料，以获得可靠且可重复的研究结果。一手资料包括对临床研究人员、医院和专科诊所的采购负责人、生产企业高管以及法规事务专家进行结构化访谈。此外，还对临床试验註册库、同行评审文献、专利和监管申报文件进行了系统性回顾，以梳理研发轨迹并识别新兴科学主题。

为了检验我们的研究结果，我们的分析融合了供应链图谱、近期启动专案的用例，并结合技术资料和相关人员的观点进行三角验证。品管包括将访谈结果与已记录的证据进行交叉检验、反覆的专家评审以及针对策略影响的敏感性检查。最终形成的方法论兼顾了洞察的深度和证据来源的透明度，从而为推进抗病毒疗法研发和商业化的决策者提供切实可行的建议。

抗病毒疗法的长期成功取决于创新、营运韧性和市场适用性证据的产生。战略意义已整合

抗病毒疗法正处于一个动态的十字路口，技术创新、监管变革和市场力量既带来了机会，也带来了挑战。科学进步不断拓展治疗套件，而营运和政策的转变则对供应链的韧性和以市场为导向的证据产生提出了更高的要求。能够将前沿科学与灵活的生产製造、适应性强的临床策略和本地化的商业化方案相结合的机构将取得最大的成功。

展望未来，最有效的项目将是那些能够预测抗药性动态、优先考虑以患者为中心的服务模式，并在生产和分销网络中建立可持续伙伴关係。透过将科学目标与实际执行相结合，相关人员可以加速将实验室突破转化为能够带来可衡量的临床和公共卫生效益的治疗方法。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基于mRNA的抗病毒疗法针对新出现的病毒株取得了快速进展
  • 将人工智慧应用于抗病毒候选药物的筛检和优化
  • 在病毒感染的治疗中，抗体和小分子联合治疗的应用日益增加。
  • 长效注射型抗病毒药物的出现，为持续控制慢性病毒性疾病提供了可能。
  • 开发广谱、宿主特异性抗病毒药物以防止抗药性的产生
  • 拓展可吸入奈米颗粒製剂，以改善标靶抗病毒肺部递送。
  • 在临床环境中透过病毒基因分型和抗药性分析进行个人化抗病毒治疗
  • 基于 CRISPR-Cas 的基因编辑方法正在进行临床评估，用于破坏目标病毒基因组。
  • 透过整合电子健康记录的真实世界证据，监测抗病毒药物安全性和有效性的趋势

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章：以疾病类型分類的抗病毒治疗市场

  • COVID-19
  • 巨细胞病毒
  • C型肝炎
  • 疱疹
  • HIV
  • 流感
  • 呼吸道融合病毒（RSV）

9. 按药物类别分類的抗病毒治疗市场

  • 融合抑制剂
  • 整合酶抑制剂
  • 干扰素
  • 单株抗体
  • 神经氨酸酶抑制剂
  • NNRTI
  • NRTI
  • 聚合酵素抑制剂
  • 蛋白酶抑制剂

第十章 依给药途径分類的抗病毒治疗药物市场

  • 吸入
  • 注射
  • 口服
  • 局部的

第十一章 按分销管道分類的抗病毒治疗市场

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科诊所

第十二章：按治疗类型分類的抗病毒治疗市场

  • 预防
  • 治疗

第十三章：各地区抗病毒治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗病毒治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国抗病毒治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company
    • Novartis AG
    • AstraZeneca PLC
Product Code: MRR-037F3DB2591D

The Antiviral Therapeutics Market is projected to grow by USD 157.02 billion at a CAGR of 8.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 82.01 billion
Estimated Year [2025] USD 88.89 billion
Forecast Year [2032] USD 157.02 billion
CAGR (%) 8.45%

Comprehensive orientation to the modern antiviral therapeutics landscape that integrates scientific progress, regulatory realities, and commercial strategy for decision-makers

The antiviral therapeutics landscape stands at the confluence of accelerated scientific discovery, shifting public health expectations, and intensifying commercial competition. Recent years have seen novel modalities and delivery technologies transition from proof-of-concept to clinical reality, catalyzing a more complex but opportunity-rich environment for developers, manufacturers, and payers. Stakeholders must now reconcile therapeutic innovation with cost pressures, supply chain vulnerabilities, and evolving regulatory standards across key global jurisdictions.

As the pathogen spectrum broadens and the emphasis on pandemic preparedness grows, organizations must recalibrate their strategic priorities. Investments in broad-spectrum platforms, host-targeted approaches, and adaptive manufacturing have risen in prominence. At the same time, payers and procurement bodies increasingly scrutinize clinical value and real-world effectiveness, prompting sponsors to design evidence generation strategies that extend beyond pivotal trials. Consequently, leaders who integrate scientific rigor with commercial foresight and operational resilience will shape the next phase of antiviral therapeutics development and delivery.

How converging platform technologies, regulatory innovations, and manufacturing agility are fundamentally altering antiviral drug discovery, development, and delivery

A series of transformative shifts is reshaping how antiviral drugs are discovered, developed, and delivered. Platform technologies that proved adaptable during urgent public health crises are now being repurposed toward a wider range of viral targets, enabling faster lead identification and more agile development pathways. Simultaneously, the maturation of monoclonal antibody engineering and the refinement of host-directed therapies are expanding therapeutic options beyond traditional small-molecule inhibitors.

Digital capabilities and artificial intelligence have accelerated target discovery and optimized candidate selection, while modular and single-use manufacturing solutions are reducing lead times and increasing geographic flexibility. These scientific and operational changes are complemented by regulatory innovation, where expedited pathways and adaptive trial designs are facilitating conditional access for high unmet need indications. Taken together, these shifts underscore a landscape where technological convergence, regulatory agility, and manufacturing adaptability determine commercial success.

Assessing the cumulative operational and strategic consequences of recent United States tariff measures on antiviral supply chains, procurement, and manufacturing decisions

Policy changes and trade measures implemented in 2025 have introduced a new variable into global antiviral supply chains and procurement strategies. Tariff adjustments impacting key raw materials and finished pharmaceuticals have elevated the cost calculus for cross-border sourcing, prompting firms to re-evaluate supplier networks and inventory strategies. In response, many organizations have accelerated efforts to localize production, expand contract manufacturing partnerships, and diversify active pharmaceutical ingredient suppliers to mitigate single-source exposure.

Beyond immediate cost implications, tariffs have influenced long-term strategic choices. Sponsors and manufacturers have revisited site selection decisions for new facilities, factoring in tariff risk alongside labor, talent availability, and regulatory alignment. Procurement organizations in hospitals, retail pharmacies, and specialty clinics have adapted contracting approaches to include greater flexibility around supply guarantees and price escalators. Ultimately, the cumulative impact of trade measures has crystallized the need for resilient, multi-layered supply strategies that preserve continuity of care while maintaining commercial viability.

Strategic segmentation insights tying disease targets, drug classes, administration routes, distribution channels, and therapy objectives to clinical and commercial decision-making

Segmentation-driven analysis reveals differentiated dynamics across therapeutic targets and modalities that should inform portfolio and commercialization choices. Disease-specific considerations vary markedly: responses to acute respiratory viruses demand rapid onset and convenient administration, whereas chronic infections such as hepatitis C and HIV prioritize sustained viral suppression, adherence support, and resistance management. Emerging and re-emerging targets like cytomegalovirus and respiratory syncytial virus require specialized clinical development approaches and often benefit from targeted biologics or prophylactic strategies.

Drug-class distinctions influence development timelines and deployment. Small-molecule polymerase and protease inhibitors typically offer oral dosing advantages and established manufacturing footprints, while monoclonal antibodies and interferons frequently rely on injectable formats and complex biologics production. Fusion and integrase inhibitors, as well as nucleoside and non-nucleoside reverse transcriptase inhibitors, each carry distinct resistance profiles and combination therapy implications. Route of administration further shapes uptake and adherence: oral agents facilitate outpatient treatment and retail pharmacy distribution, injectable formulations often necessitate hospital or specialty clinic involvement, inhalation and topical options serve niche respiratory and localized indications, and delivery mode directly affects reimbursement pathways and patient preference.

Distribution-channel strategies must align with both product attributes and health system capabilities. Hospital pharmacies and specialty clinics play critical roles for parenteral biologics and complex therapeutics that require monitoring, whereas retail and online pharmacies expand access for oral antivirals and prophylactic products. Finally, the therapy objective-prophylaxis versus treatment-dictates clinical trial design, labeling nuances, and post-marketing evidence generation. Prophylactic products often emphasize population-level effectiveness and safety over extended periods, while therapeutic agents prioritize immediate clinical endpoints and resistance surveillance. Integrating these segmentation lenses enables targeted clinical development, tailored market access plans, and optimized commercial deployment.

Regional dynamics and market access imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape development, manufacturing, and commercialization choices

Regional variations create distinct operational and regulatory environments that influence pipeline prioritization and go-to-market tactics. In the Americas, robust clinical trial infrastructure, substantial public and private R&D investment, and a complex reimbursement landscape require evidence packages that demonstrate comparative effectiveness and value over existing standards. Regulatory pathways in this region also accommodate accelerated access mechanisms for high-priority therapies, but stakeholders must navigate pricing scrutiny and payer-driven utilization controls.

Europe, Middle East & Africa present heterogenous regulatory frameworks and procurement models, with some markets emphasizing centralized evaluation and others relying on national assessment and tendering processes. This diversity necessitates nuanced market access strategies that balance regional dossiers with country-level evidence and pricing flexibility. In Asia-Pacific, rapid adoption of innovative platforms, a growing biomanufacturing base, and expanding private and public healthcare investment create fertile ground for strategic partnerships and regional manufacturing hubs. Nevertheless, differences in regulatory timelines, intellectual property enforcement, and local clinical practice patterns require tailored commercialization roadmaps. Across all regions, cross-border trade measures, local production incentives, and digital health adoption will continue to shape supply chain design and market entry sequencing.

Company-level imperatives showing how large pharmaceutical networks, specialized biotechs, and manufacturing partners align to advance antiviral innovation and commercialization

Company strategies reveal a bifurcated ecosystem where large integrated pharmaceutical firms and nimble biotechs pursue complementary pathways to innovation. Established multinationals leverage deep regulatory expertise, broad manufacturing networks, and global commercial reach to advance late-stage programs and scale complex biologics. In parallel, specialized biotechs focus on high-impact science, rare or orphan viral targets, and disruptive modalities, increasingly relying on strategic alliances, licensing arrangements, and milestone-driven collaborations to accelerate clinical development and access capital.

Contract development and manufacturing organizations have become pivotal ecosystem partners, enabling rapid scale-up and geographic diversification without the fixed-cost burden of new facilities. In addition, novel entrants specializing in delivery technologies, diagnostics, and data-driven clinical optimization are reshaping how companies design value propositions. Across the competitive landscape, successful organizations align scientific differentiation with pragmatic commercialization plans, prioritize durable manufacturing relationships, and commit to post-approval evidence generation that supports adoption in diverse healthcare systems.

Practical, cross-functional recommendations for executives to enhance resilience, accelerate access, and optimize commercialization across the antiviral therapeutic value chain

Industry leaders should adopt integrated strategies that combine scientific differentiation with operational resilience and market-focused evidence generation. First, diversify supplier networks for key raw materials and biologics components while establishing dual-source agreements and safety-stock policies to reduce disruption risk. Simultaneously, invest in flexible and geographically distributed manufacturing capacity, including partnerships with contract manufacturers that can pivot across modalities.

Second, prioritize platform technologies and combination approaches that address resistance and broaden the therapeutic window, while designing clinical programs with real-world endpoints and adaptive elements to support accelerated access. Third, align distribution strategies with product profiles by optimizing channels for adherence, access, and monitoring; for instance, pair oral therapies with online pharmacy programs and digital adherence tools, and route injectable biologics through specialty clinics with integrated patient support. Fourth, create pricing and contracting frameworks that reflect value over the product lifecycle, incorporate outcomes-based elements where feasible, and anticipate payer requirements across regions. Finally, strengthen cross-functional collaborations-linking R&D, regulatory, manufacturing, and commercial teams-to ensure that development decisions incorporate downstream deployment realities and that evidence strategies support sustainable uptake.

Rigorous multi-method research approach blending primary stakeholder interviews, clinical and regulatory review, supply chain mapping, and iterative expert validation to ensure actionable insights

The research approach combined multi-modal primary and secondary methods to ensure robust, reproducible insights. Primary engagements included structured interviews with clinical investigators, procurement leaders in hospitals and specialty clinics, manufacturing executives, and regulatory affairs specialists. These qualitative inputs were complemented by systematic reviews of clinical trial registries, peer-reviewed literature, patents, and regulatory filings to map development trajectories and identify emergent scientific themes.

To validate findings, the analysis incorporated supply chain mapping exercises, case studies of recent program launches, and triangulation of technical data with stakeholder perspectives. Quality controls included cross-validation between interview outputs and documentary evidence, iterative expert review cycles, and sensitivity checks on strategic implications. The result is a methodology that balances depth of insight with transparency of evidence sources and that supports pragmatic recommendations for decision-makers navigating antiviral therapeutic development and commercialization.

Synthesis of strategic implications where innovation, operational resilience, and market-aligned evidence generation determine long-term success in antiviral therapeutics

Antiviral therapeutics occupy a dynamic juncture where technological innovation, regulatory evolution, and market forces converge to create both opportunity and complexity. Scientific advances are expanding the therapeutic toolkit, while operational and policy shifts demand greater supply chain resilience and market-focused evidence generation. Success will favor organizations that can integrate cutting-edge science with flexible manufacturing, adaptive clinical strategies, and regionally tailored commercialization plans.

Looking ahead, the most effective programs will be those that anticipate resistance dynamics, prioritize patient-centric delivery models, and establish durable partnerships across manufacturing and distribution networks. By aligning scientific ambition with pragmatic execution, stakeholders can accelerate the translation of laboratory breakthroughs into therapies that deliver measurable clinical and public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid advancement of mRNA-based antiviral therapeutics targeting emerging viral strains
  • 5.2. Integration of artificial intelligence in antiviral drug candidate screening and optimization
  • 5.3. Growing adoption of combination antibody and small molecule therapies for viral infection management
  • 5.4. Emergence of long acting injectable antivirals for sustained suppression of chronic viral diseases
  • 5.5. Development of broad-spectrum host-directed antivirals to reduce resistance development
  • 5.6. Expansion of inhalable nanoparticle formulation to improve targeted antiviral lung delivery
  • 5.7. Personalized antiviral regimens guided by viral genotyping and resistance profiling in clinics
  • 5.8. CRISPR-Cas based gene editing approaches under clinical evaluation for targeted viral genome disruption
  • 5.9. Real world evidence integration from electronic health records to monitor antiviral safety and efficacy trends

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Therapeutics Market, by Disease Type

  • 8.1. Covid-19
  • 8.2. Cytomegalovirus
  • 8.3. Hepatitis C
  • 8.4. Herpes
  • 8.5. Hiv
  • 8.6. Influenza
  • 8.7. Respiratory Syncytial Virus

9. Antiviral Therapeutics Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Interferons
  • 9.4. Monoclonal Antibodies
  • 9.5. Neuraminidase Inhibitors
  • 9.6. Nnrtis
  • 9.7. Nrtis
  • 9.8. Polymerase Inhibitors
  • 9.9. Protease Inhibitors

10. Antiviral Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Specialty Clinics

12. Antiviral Therapeutics Market, by Therapy Type

  • 12.1. Prophylaxis
  • 12.2. Treatment

13. Antiviral Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. AbbVie Inc.
    • 16.3.3. F. Hoffmann-La Roche Ltd.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Pfizer Inc.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. GlaxoSmithKline plc
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. Novartis AG
    • 16.3.10. AstraZeneca PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THE